Adrabetadex - CTD Holdings

Drug Profile

Adrabetadex - CTD Holdings

Alternative Names: HP-Beta-CD - CTD Holdings; HP-β-CD - CTD Holdings; Hydroxypropyl-beta-cyclodextrin - CTD Holdings; Trappsol® Hydroxypropyl Beta Cyclodextrin-Endotoxin Controlled (THPB-EC) grade - CTD

Latest Information Update: 04 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CTD Holdings
  • Class Antidementias; Beta-Cyclodextrins
  • Mechanism of Action Binding agents; Cholesterol modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Niemann-Pick disease type C
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Niemann-Pick disease type C
  • Preclinical Alzheimer's disease
  • Research Diabetic nephropathies; Peripheral arterial disorders; Viral infections

Most Recent Events

  • 30 Apr 2018 US FDA authorizes an application submitted by CTD holdings to initiate an open-label phase I extension trial in USA
  • 30 Apr 2018 CTD Holdings plans an open-label phase I extesnion trial for Niemann-Pick disease type C in USA
  • 20 Apr 2018 CTD Holdings finalises cooperative research agreement with Kerwin Research Center for the development of cyclodextrin therapy in Alzheimer's Disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top